Indeed, challenging FXR−/− mice with ritonavir exacerbated the severity of dyslipidemia induced by ritonavir causing a two-fold increase in FFA, triacylglycerols and LDL plasma levels in comparison to wild type mice administered the HIP-PI. This evidence concerns the gene NR1H4 and metabolic syndrome.